This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Evaluate, Safety and Tolerability of Intraprostati...
Clinical trial

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Read time: 1 mins
Last updated:13th Jul 2015

To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.


Study Type: Interventional

Endpoint Classification: Safety Study

Intervention Model: Single Group Assignment

Masking: Open Label

Primary Purpose: Treatment

Official Title: Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion

Estimated Enrollment: 20

Study Start Date: May 2015

Estimated Study Completion Date: February 2016

Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)


Experimental: Intraprostatic administration


Category Value
Study start date 2015-07-13

View full details